| Gene symbol | B2M | Synonyms | AMYLD6, IMD43, MHC1D4 | Type of gene | protein-coding |
| Chromosome | 15 | Map location | 15q21.1 | dbXrefs | |
| Gene perturbation-related omics dataset | PerturbAtlas | ||||
| Description | beta-2-microglobulin | ||||
| Gene symbol | HLA-B | Synonyms | AS, B-4901, HLAB | Type of gene | protein-coding |
| Chromosome | 6 | Map location | 6p21.33 | dbXrefs | |
| Description | major histocompatibility complex, class I, B | ||||
| GTO ID | GTC1198 |
| Trial ID | NCT00050388 |
| Disease | Head and Neck Cancer |
| Altered gene | HLA-B|B2m |
| Therapeutic/Target gene | Therapeutic gene |
| Therapy | Gene transfer |
| Treatment | Allovectin-7 |
| Phase | Phase3 |
| Recruitment status | Completed |
| Title | Phase II Study of the Safety and Efficacy of Allovectin-7 Immunotherapy for the Treatment of Primary, Resectable Squamous Cell Carcinoma of the Oral Cavity or Oropharynx |
| Year | 2002 |
| Country | United States |
| Company sponsor | Vical |
| Other ID(s) | VCL-1005-207 |
| Vector information | |||
|
|||
| Cohort 1 | |||||
|
|||||